Modality
Fusion Protein
MOA
KRASG12Ci
Target
TYK2
Pathway
Tau
Bladder Ca
Development Pipeline
Preclinical
~Oct 2019
→ ~Jan 2021
Phase 1
~Apr 2021
→ ~Jul 2022
Phase 2
Oct 2022
→ Jul 2028
Phase 2Current
NCT04838067
1,471 pts·Bladder Ca
2022-10→2028-07·Recruiting
1,471 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2028-07-172.3y awayPh2 Data· Bladder Ca
Trial Timeline
Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3
P2
Recruit…
Catalysts
Ph2 Data
2028-07-17 · 2.3y away
Bladder Ca
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04838067 | Phase 2 | Bladder Ca | Recruiting | 1471 | EFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Voxacilimab | Pfizer | Phase 2 | TYK2 | |
| Lisolucimab | Novartis | Approved | CD20 | |
| Gozelemzoparlimab | Merck & Co | Phase 2 | FXIa | |
| MRK-3732 | Merck & Co | Phase 1 | TYK2 | |
| AZN-8478 | AstraZeneca | NDA/BLA | SHP2 | |
| Pexazasiran | Sanofi | Preclinical | FXIa | |
| Terasacituzumab | Novo Nordisk | NDA/BLA | IL-23 | |
| ALN-6288 | Alnylam | Approved | LAG-3 | |
| BMR-9762 | BioMarin | Phase 3 | Aβ | |
| Niralucimab | Ionis | Phase 1 | ALK |